retatrutide sleep apnea for the treatment of obesity, obstructive and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials Phase 3 results for retatrutide

Retatrutide (LY3437943) is an investigational medicinal product (IMP) a triple agonist peptide targeting GIP, GLP-1, and glucagon receptors currently under clinical evaluation for obesity and metabolic disease

An estimated 1 in 7 GLP-1 users has already tried microdosing.* * Based on a 2026 survey of 8,000+ GLP-1 users

People who use this window wisely, who build robust exercise routines, who restructure their food environment, who develop new coping mechanisms for stress that do not involve food, are the ones most likely to maintain results long-term

Cysteine-rich secretory proteins (CRISPs) from venomous snakes: an overview of the functional diversity in a large and underappreciated superfamily